(Q38066200)

28 August 2017

Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

28 August 2017

0 references

1 reference

Sheng-Lan Wang

1

1 reference

PMCID

3494118

28 August 2017

Zhi-Rong Wang

series ordinal

2

1 reference

PMCID

3494118

28 August 2017

Chang-Qing Yang

series ordinal

3

1 reference

28 August 2017

20 September 2012

1 reference

Experimental and Therapeutic Medicine

28 August 2017

1 reference

28 August 2017

4

1 reference

28 August 2017

1051-1056

1 reference

28 August 2017

6

1 reference

Antibiotics and probiotics in inflammatory bowel disease: why, when, and how

28 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Adherent-invasive Escherichia coli and Crohnʼs disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Guidelines for the management of inflammatory bowel disease in adults

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Inflammatory Bowel Disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Double blind, placebo controlled trial of metronidazole in Crohn's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Metronidazole in Crohn's disease. A double blind cross-over clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Preliminary study of ciprofloxacin in active Crohn's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494118

The genetics of inflammatory bowel disease

31 August 2018

1 reference

12 December 2020

Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

1 reference

12 December 2020

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

12 December 2020

Impact of Clostridium difficile on inflammatory bowel disease

1 reference

12 December 2020

Combination ciprofloxacin and metronidazole for active Crohn's disease

1 reference

12 December 2020

A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial

1 reference

12 December 2020

The efficacy of tobramycin in the treatment of ulcerative colitis

1 reference

12 December 2020

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

1 reference

12 December 2020

Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis

1 reference

12 December 2020

Identifiers

DOI

10.3892/ETM.2012.718

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

PMCID

3494118